Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug
  Response by Zhu, Yitan et al.
 1 
  
 
Ensemble Transfer Learning for the Prediction of Anti-Cancer 
Drug Response 
 
 
 
Yitan Zhu1*, Thomas Brettin1, Yvonne A. Evrard2, Alexander Partin1, Fangfang Xia1, Maulik 
Shukla1, Hyunseung Yoo1, James H. Doroshow3, Rick Stevens1,4 
 
 
 
1. Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, IL, USA 
 
2. Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc. 
Frederick, MD, USA 
 
3. Developmental Therapeutics Branch, National Cancer Institute, Frederick, MD, USA 
 
4. Department of Computer Science, The University of Chicago, Chicago, IL, USA 
 
 
*Correspondence: yitan.zhu@anl.gov 
  
 2 
Abstract 
 
Transfer learning has been shown to be effective in many applications in which training 
data for the target problem are limited but data for a related (source) problem are abundant. In this 
paper, we apply transfer learning to the prediction of anti-cancer drug response. Previous transfer 
learning studies for drug response prediction focused on building models that predict the response 
of tumor cells to a specific drug treatment. We target the more challenging task of building general 
prediction models for transfer learning that can make predictions for both new tumor cells and new 
drugs. While existing works focused on either building transformations of features and prediction 
targets between datasets or combining the source dataset with some auxiliary dataset for prediction, 
we apply the classic transfer learning framework that trains a prediction model on the source 
dataset and refines it on the target dataset, and extends the framework through ensemble. We 
implement the ensemble transfer learning framework using LightGBM and two deep neural 
network (DNN) models with different architectures. Uniquely, we investigate the power of transfer 
learning for three application settings including drug repurposing, precision oncology, and new 
drug development, through different data partition schemes in cross-validation. We test the 
proposed ensemble transfer learning on benchmark in vitro drug screening datasets, taking one 
dataset as the source domain and another dataset as the target domain. The analysis results 
demonstrate the benefit of applying ensemble transfer learning for predicting anti-cancer drug 
response in all three applications with both LightGBM and DNN models. Compared between the 
different prediction models, a DNN model with two subnetworks for the inputs of tumor features 
and drug features separately outperforms LightGBM and the other DNN model that concatenates 
tumor features and drug features for input in the drug repurposing and precision oncology 
applications. In the more challenging application of new drug development, LightGBM performs 
better than the other two DNN models, probably due to the limited number of drugs in the training 
set. 
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Introduction 
 
Cancer is a complex, dynamic, and heterogenous disease. Patients with the same cancer 
histology can respond differently to the same anti-cancer therapy [Wu et al., 2017]. Multiple in 
vitro drug screening studies have been conducted generating data about drug efficacy on cancer 
cell lines (CCLs) [Shoemaker, 2006; Basu et al., 2013; Yang et al., 2013; Barretina et al., 2012; 
Haverty et al., 2016]. Due to the heterogeneity of cancer, an accurate prediction of the response of 
cancer cells to a drug treatment is of paramount importance for therapeutics development and 
patient care. There are three major applications for drug response prediction including drug 
repurposing, precision oncology, and new drug development. The goal of drug repurposing is to 
examine whether an existing drug used to treat a specific cancer indication can be used to treat 
another cancer indication. In drug repurposing, both the drug and cancer are not new but their 
combination has not been previously tested. For precision oncology, the goal is to identify an 
existing drug to treat a new cancer case that has not been investigated or treated before. The 
development of new drugs requires predicting the response of known cancer cases under the 
treatment of a new drug that has not been tested before. 
 
Various methods and analysis schemes have been developed and used for predicting anti-
cancer drug response, which can be categorized in different ways. Conventional machine learning 
methods, such as ridge and elastic net regressions [Jang et al., 2014], random forests regression 
[Costello et al., 2014], and support vector machine [Huang et al., 2017], have been used in drug 
response prediction. Recently, deep learning methods have started to play an increasingly 
important role [Xia et al., 2018; Manica et al., 2019; Rampášek et al., 2019; Chang et al., 2018]. 
Some studies predicted dose-dependent cell growth inhibition [Xia et al., 2018], and many others 
predicted dose-independent drug response measurements, such as the area under the dose response 
curve (AUC) and the half maximal inhibitory concentration (IC50) [Rampášek et al., 2019; Menden 
et al., 2013; Huang et al., 2017]. Some analyses have constructed a prediction model for an 
individual cancer type and/or drug [Rampášek et al., 2019; Smith et al., 2010; Fowles et al., 2016], 
while others have built general prediction models covering multiple cancer types and/or drugs [Xia 
et al., 2018; Chang et al., 2018; Menden et al., 2013; Manica et al. 2019]. While transcriptomic 
data and other omics data, such as genome and proteomic data, have been used for the prediction 
of drug response, transcriptomic data have been shown to be the most predictive among all omic 
modalities [Costello et al., 2014; Jang et al., 2014]. Most works have targeted the prediction of 
single drug response [Lee et al., 2007; Menden et al., 2013; Rampášek et al., 2019], though some 
predicted the response of drug combinations [Xia et al., 2018; Menden et al., 2019]. 
 
In this paper, we investigate the application of transfer learning for drug response 
prediction. The general goal of transfer learning is to build a high-performance learner for a target 
domain where data availability is limited using information from a related source domain with 
abundant data [Weiss et al., 2016; Pan et al., 2010]. Transfer learning has been used in many areas, 
such as text classification [Duan et al., 2012; Wang et al., 2011] and image classification [Duan et 
al., 2012; Kulis et al., 2011]. Deep transfer learning implements transfer learning with deep neural 
network (DNN) models [Tan et al., 2018; Huang et al., 2013; Oquab et al., 2014]. One popular 
deep transfer learning technique is to transfer the front layers of a DDN model trained in the source 
domain to the target domain and use it as a feature extractor [Oquab et al., 2014; Huang et al., 
2013]. Based on the target domain data, either the parameters of the back layers are refined or the 
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back layers are removed and new layers are added behind the front layers and trained from scratch. 
The idea behind this approach is that the DNN model forms an iterative and continuous abstraction 
process and the front layers may generate features informative in both domains [Tan et al., 2018]. 
Transfer learning has also been used for drug response prediction. Dhruba et al. utilized one drug 
screening dataset to help the prediction on another drug screening dataset through transfer learning, 
which either transforms the two datasets into a unified latent space or transforms one dataset to the 
space of the other dataset through regression mappings [Dhruba et al., 2018]. Turki et al. developed 
approaches to combine a drug screening dataset with auxiliary data for predicting patient treatment 
response [Turki et al., 2017; Turki et al., 2018]. Borisov et al. predicted the response of a patient 
to a drug treatment by building a prediction model for the patient using cell lines similar to the 
patient evaluated by gene expressions of selected drug-related pathways [Borisov et al., 2018].  
  
 While existing works on transfer learning for drug response prediction focus on building 
prediction models for a specific drug [Dhruba et al., 2018; Turki et al., 2017; Turki et al., 2018; 
Borisov et al., 2018], we target the more challenging task of building general prediction models 
through transfer learning that can predict the response of not only new cancer cases but also new 
drugs. Uniquely, we test the power of transfer learning for three drug response prediction 
applications including drug repurposing, precision oncology, and new drug development, via 
different data partition schemes in cross-validation. Also, different from the previous studies, we 
apply the classic transfer learning scheme that trains a prediction model on the source dataset and 
then refines it on the target dataset, and extend the scheme through ensemble prediction by training 
and refining multiple models. We implement the analysis pipeline using three prediction models, 
including LightGBM [Ke et al., 2017], a representative and efficient gradient boosting algorithm, 
and two DNN models of different architectures. We apply ensemble transfer learning on multiple 
in vitro CLL drug screening datasets simulating the three different drug response prediction 
applications. Based on the results, we compare the prediction performance with and without 
transfer learning and also compare between transfer learning using different prediction models for 
each application. 
 
 
 
Data and Methods 
 
Drug Response Data, Gene Expressions, and Drug Descriptors 
 
 Our study involves four public in vitro drug screening datasets, including the Cancer 
Therapeutics Response Portal v2 (CTRP) [Basu et al., 2013], the Genomics of Drug Sensitivity in 
Cancer (GDSC) [Yang et al., 2013], the Cancer Cell Line Encyclopedia (CCLE) [Barretina et al., 
2012], and the Genentech Cell Line Screening Initiative (GCSI) [Haverty et al., 2016]. The drug 
response values of these datasets are the percentages of tumor cell growth under a drug treatment 
at multiple doses. We used the three-parameter logistic function (hill slope model) to fit the tumor 
cell growth values and generate dose response curves. Based on the dose response curve, we 
calculated the area under the dose response curve (AUC) for the dose range of [10−10 M, 10−4 M]. 
The AUC value was then normalized by the dose range, so that after normalization, the AUC value 
is between 0 and 1, representing the treatment effect. 0 indicates complete response and 1 indicates 
no response. Table 1 shows the number of treatments (pairs of drugs and CCLs) in each dataset. 
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In some studies, a drug and CCL pair may have been tested multiple times. In these cases, we 
averaged the AUC values across the experiments so that the number of treatments in Table 1 
reflects the number of unique drug and CCL pairs in a dataset. Fig. 1 shows the histogram of AUC 
values with the mean and standard deviation in each dataset. Clearly, the distribution of AUC 
values varies between datasets. 
 
 
 
 
 
Figure 1    Histograms of drug response AUC values in datasets. Mean and standard deviation 
(std) of AUC values are shown on the top left of each histogram.  
 
 
 
CCLs are represented by their gene expression data in prediction modeling. The gene 
expression data were collected from the CCLE online resource. All CCLs in the other three studies, 
i.e., GCSI, CTRP, and GDSC, were also used in the CCLE study, except 11 GDSC CCLs that 
were thus excluded from the analysis. The gene expression data were generated using RNA 
sequencing, and TPMs (transcripts per kilobase million) were calculated as expression values, 
which were log2 transformed and then standardized so that each gene has a 0 mean and a unit 
standard deviation. Instead of using all transcripts for analysis, we focused the analysis on genes 
potentially related to cancer genetic mechanism, genomic regulation, and drug response. We 
selected 1,927 genes, including “landmark” genes well-representing cellular transcriptomic 
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changes identified in the Library of Integrated Network-Based Cellular Signatures (LINCS) 
project [Subramanian et al., 2017] and cancer-related genes collected from OncoKB [Chakravarty 
et al., 2017] and GDSC [Iorio et al., 2016].  
 
Drugs are represented by molecular descriptors in prediction modeling. The Dragon 
(version 7.0) software package (https://chm.kode-solutions.net/products_dragon.php) was used to 
compute numeric descriptors of the drugs based on their molecular structure. The package 
calculated various types of descriptors, such as the simplest atom types, functional groups and 
fragment counts, topological and geometrical descriptors, estimations of molecular properties, and 
drug-like and lead-like indices. We removed the descriptors with missing values and kept 1,623 
molecular descriptors for the analysis. 
 
 
 
Table 1.    Numbers of CCLs, drugs, and treatments (pairs of drugs and CCLs) in each dataset.  
 
Dataset # CCLs # Drugs # Treatments 
GCSI 357 16 5,647 
CCLE 474 24 10,971 
GDSC 659 238 125,712 
CTRP 812 494 318,040 
 
 
 
Framework of Analysis Scenario 
 
 A goal of our study is to investigate whether ensemble transfer learning can improve the 
prediction of drug response compared to not using transfer learning. The ensemble transfer 
learning (ETL) first train prediction models on the source dataset and then refine them on a part of 
the target dataset. After refinement, the models are applied on the rest of the target dataset to make 
ensemble predictions. The prediction performance is then evaluated and compared to those of 
baseline schemes that build prediction models based on only the target data. Two baseline schemes 
without transfer learning are used, standard cross-validation (SCV) and ensemble cross-validation 
(ECV). The analysis schemes of SCV and ECV will be introduced in detail later. The prediction 
performances of the three analysis schemes are compared to each other. See Fig. 2 for the 
framework of the analysis scenario. For a fair comparison, the data partition used for model 
training, validation, and testing in the baseline schemes are exactly the same as the data partition 
used for model refinement, validation, and testing in transfer learning on the target dataset in 
corresponding cross-validation trials, respectively. The validation set is used for hyperparameter 
tuning and early stopping of model training or refinement. In Fig. 2, 8-1-1 cross-validation means 
dividing the data into 10 data folds and using 8, 1, and 1 data fold for model training, validation, 
and testing, respectively. 8-1-1 cross-validation is used at the first step of transfer learning to train 
models on the source dataset. 1-1-8 cross-validation means dividing the data into 10 data folds and 
using 1, 1, and 8 data folds for model training (or refinement), validation, and testing, respectively. 
1-1-8 cross-validation is used for all analyses on the target data, including SCV, ECV, and the 
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second step of transfer learning, to simulate a situation where the training data at the target domain 
are quite limited. For transfer learning, we use the two large datasets CTRP and GDSC (see Table 
1) as the source data and use the two small datasets CCLE and GCSI as the target data, which 
forms 4 transfer learning tasks denoted by CTRP ® CCLE, CTRP ® GCSI, GDSC ® CCLE, and 
GDSC ® GCSI.  
 
 
 
 
Figure 2    Analysis scenario framework. The analysis scheme on the left is ensemble transfer 
learning (ETL). The middle and right analysis schemes are standard cross-validation (SCV) and 
ensemble cross-validation (ECV), respectively, which do not apply transfer learning but instead 
analyze only the target dataset. 
 
 
 
Standard and Ensemble Cross-Validations  
  
 Fig. 3a shows the flowchart for standard cross-validation (SCV), in which data are divided 
into three parts for model training, validation, and testing. In the first step of transfer learning, we 
apply the 8-1-1 SCV on the source dataset to generate the models to be transferred. The 1-1-8 SCV 
is applied on the target data as a baseline to be compared with transfer learning. The ensemble 
cross-validation (ECV) also follows the flowchart in Fig. 3a but with the part indicated by the 
dashed-line box replaced by the flowchart in Fig. 3b, which performs ensemble learning by 
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resampling the training set. We apply the 1-1-8 ECV on the target data as a second baseline to be 
compared with transfer learning. Notice that SCV, ECV, and ETL on the same target dataset 
always use the same data partition (i.e., training, validation, and testing sets) in corresponding 
cross-validation trials so that the prediction performances obtained by the analyses can be 
compared. 
 
 
 
 
Figure 3    (a) Flowchart of standard cross-validation (SCV). (b) The ensemble cross-validation 
(ECV) also follows the flowchart in (a), but with the part indicated by the dashed-line box replaced 
by the flowchart in (b).  
 
 
 
Ensemble Transfer Learning Scheme 
 
 Fig. 4 shows the flowchart for ensemble transfer learning (ETL), which retrieves the 10 
models trained on the source dataset and refines these models on the training set of the target data. 
The refined models are then used to predict the testing samples in the target data, where their 
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prediction outcomes are averaged to generate the ensemble prediction. We apply the ETL analysis 
for each of the four transfer learning tasks.  
 
 
 
 
Figure 4    Flowchart of ensemble transfer learning (ETL). 
 
 
 
Three Data Partition Schemes Representing Different Drug Response Prediction 
Applications 
 
We investigate the power of transfer learning for three different drug response prediction 
applications including drug repurposing, precision oncology, and new drug development. We 
design three data partition/selection schemes to simulate the three different applications for 
transfer learning tasks. For the purpose of evaluating generalization prediction performance, there 
should be no treatment (combination of CCL and drug) shared by the source and target datasets in 
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analysis. Thus, we removed the overlapping treatments from the source dataset, so that they are 
included only in the target dataset. For drug repurposing, no additional data removal or selection 
was needed. See Section A of Table 2 for the numbers of CCLs, drugs, and treatments in the source 
dataset after removing overlapping treatments in each transfer learning task.  
 
For the application of precision oncology, we further removed all treatments of CCLs from 
the source dataset that are also included in the target dataset, because the general goal of precision 
oncology is to select a drug for treating a tumor that has not been seen before. Also, when 
performing cross-validations on both the target and source datasets, the data folds were always 
generated to have random but different CCLs. In other words, no CCL was shared between data 
folds, which guaranteed that different CCLs were used for model training/refinement, validation, 
and testing, strictly simulating the precision oncology setup. See Section B of Table 2 for the 
numbers of CCLs, drugs, and treatments in the source dataset after removing overlapping CCLs 
in each transfer learning task. We can see the numbers of CCLs and treatments are significantly 
reduced compared to the numbers in Section A of Table 2.  
 
For the application of new drug development, we removed all treatments of drugs from the 
source dataset that are also included in the target dataset, because the goal is to discover new drugs 
that can treat existing cancer cases. When performing cross-validations on both the target and 
source datasets, the data folds were always randomly generated to have different drugs, which 
guaranteed different drugs were used for model training/refinement, validation, and testing. See 
Section C of Table 2 for the numbers of CCLs, drugs, and treatments in the source dataset after 
removing overlapping drugs in each transfer learning task.  
 
 
 
Table 2.    Numbers of CCLs, drugs, and treatments in source datasets after removing overlap 
between source and target datasets, with different data partition/selection schemes.   
 
Transfer 
learning task 
Section A: removal of overlap 
treatments for drug repurposing 
Section B: removal of overlap 
CCLs for precision oncology 
Section C: removal of overlap drugs 
for new drug development 
Target Source # CCLs # Drugs # Treatments # CCLs # Drugs # Treatments # CCLs # Drugs # Treatments 
CCLE  CTRP  812 494 311,194 376 494 143,634 812 477 305,278 
CCLE GDSC 659 238 123,447 282 238 53,743 659 225 121,174 
GCSI CTRP  812 494 314,469 479 494 185,138 812 482 309,363 
GCSI GDSC 659 238 123,141 343 238 64,664 659 224 120,045 
 
 
  
DNN and LightGBM Prediction Models 
 
 We take drug response prediction as a regression problem to predict the AUC value and 
use the mean squared error (MSE) as the loss function in training. LightGBM is an efficient 
implementation of the Gradient Boosting Decision Tree (GBDT) [Friedman, 2001] using 
techniques of gradient-based one-side sampling and exclusive feature bundling to speed up model 
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training [Ke et al., 2017]. We used the LightGBM Python package 
(https://LightGBM.readthedocs.io/en/latest/index.html) for implementation. In transfer learning, 
the refinement of a LightGBM model was realized by adding additional boosting steps (decision 
trees) to fit the training set of the target data. The model training/refinement process would be 
stopped early if the loss on the validation set did not reduce in 150 boosting steps; otherwise the 
whole process took 1,500 boosting steps. For the other parameters of the LightGBM model, we 
used the default values.  
 
We used the Keras package (https://keras.io/) with Tensorflow 
(https://www.tensorflow.org/) backend for implementing DNN models. Two DNN models with 
different architectures were implemented (see Fig. 5). The first DNN model is composed of 7 
hidden fully connected (dense) layers with the number of nodes consecutively halved from the 
first hidden layer to the last hidden layer (Fig. 5a). The gene expressions of a CCL and the drug 
descriptors of a drug are concatenated to form the input. The second DNN model contains two 
subnetworks of 3 hidden dense layers, one for the input of gene expressions and the other for the 
input of drug descriptors (Fig. 5b). The outputs of the two subnetworks are concatenated and then 
passed to the other 4 hidden dense layers before output. The number of nodes is also consecutively 
halved from the first hidden layer to the last hidden layer. For convenience, we use sDNN (single-
network DNN) and tDNN (two-subnetwork DNN) to denote the first and second DNN models, 
respectively. Both sDNN and tDNN have 7 hidden layers. Notice that although the total number 
of nodes in a hidden layer in tDNN is always larger than the number of nodes in the corresponding 
hidden layer in sDNN, the total number of trainable parameters in tDNN is significantly smaller 
than that of sDNN due to the subnetwork structure. In both models, each hidden layer has a dropout 
layer following it except the last hidden layer. All dropout layers in a model use the same dropout 
rate. In the analysis, the dropout rate was selected among 0, 0.1, 0.25, 0.45, and 0.7 by minimizing 
the validation loss. It was the only hyperparameter optimized in the model learning process. The 
Adam optimizer was used with default setting for model learning [Ba et al., 2015]. The learning 
rate was initialized at 0.001 and was reduced by a factor of 10 if the reduction of validation loss 
was smaller than 0.00001 in 10 epochs. The learning process would be early stopped if the 
reduction of validation loss was smaller than 0.00001 in 20 epochs; otherwise the full learning 
process would take 100 epochs. When refining a trained DNN model for transfer learning, we kept 
the parameters of the bottom 2 hidden layers unchanged and continued training the parameters 
associated with the top 5 hidden layers on the target dataset. The dropout rate was also re-selected 
among the five candidate values based on the validation loss. 
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Figure 5    Architectures of two DNN models used in the analysis. (a) Single-network DNN 
(sDNN) model. Gene expressions and drug descriptors are concatenated to form the input. (b) 
Two-subnetwork DNN (tDNN) model. The subnetworks take gene expressions and drug 
descriptors as inputs separately.   
 
 
 
Results 
 
Prediction Performance for Drug Repurposing Application 
 
 For the drug repurposing application, we performed ensemble transfer learning (ETL), 
standard cross-validation (SCV), and ensemble cross-validation (ECV) with three prediction 
models including LightGBM, sDNN (single-network DNN), and tDNN (two-subnetwork DNN). 
ETL was conducted for all four transfer learning tasks (i.e., CTRP ® CCLE, CTRP ® GCSI, 
GDSC ® CCLE, and GDSC ® GCSI), while SCV and ECV were conducted on the two target 
datasets, i.e., CCLE and GCSI. We used two measures to evaluate the testing prediction 
performance. The first measure is the root of mean squared error (RMSE), which is the square root 
of the loss function used by the prediction models. The second measure is the Pearson correlation 
coefficient that evaluates the variation consistency between prediction values and true values. The 
prediction performance was evaluated 10 times in the 10 cross-validation trails for each of ETL, 
SCV, and ECV. Then we examined the difference of prediction performance between ETL and 
SCV/ECV using the pair-wise t-test based on the 10 measurements of each analysis.  
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 See Table 3 for the obtained prediction performance and comparison. In all of the four 
transfer learning tasks, tDNN always outperforms the other two prediction models, i.e., lightGBM 
and sDNN, evaluated by both smaller average RMSE and larger average correlation coefficient. 
Two-tail t-tests show ETL with any prediction model always statistically significantly outperforms 
SCV and ECV with the same prediction model (p-values £ 0.05). This indicates the benefit of 
using ensemble transfer learning for anti-cancer drug response prediction. ECV always gives a 
better prediction performance than SCV when applying the same prediction model on the same 
target dataset, which shows the advantage of ensemble learning. 
   
Prediction Performance for Precision Oncology Application 
 
 Table 4 shows the prediction performance and comparison for the precision oncology 
application, with cross-validations based on hard partitioning of CCLs. Again, tDNN always 
outperforms the other two prediction models, except only when being evaluated by the correlation 
coefficient in the CTRP ® CCLE learning task. Two-tail t-tests show ETL with any prediction 
model always statistically significantly outperforms SCV and ECV with the same model (p-values 
£ 0.05), except only in the comparison of ETL (with sDNN) and ECV (with sDNN) in the learning 
task of GDSC ® CCLE. These indicate the benefit of using ensemble transfer learning for drug 
response prediction in precision oncology applications. 
 
Prediction Performance for New Drug Development Application 
 
 Table 5 shows the prediction performance and comparison for the new drug development 
application with cross-validations based on hard partitioning of drugs. Predicting the efficacy of 
new drugs is generally a more challenging task than predicting the response of new CCLs. Also, 
because there are not many drugs tested in the CCLE and GCSI studies (see Table 1), the number 
of drugs used for training or refining a prediction model on these two target datasets is no larger 
than 3, which forms a very difficult prediction problem. It is not surprising to see that the prediction 
performance of ETL is worse for new drug development than for precision oncology and drug 
repurposing. But interestingly ETL also shows a higher improvement on the prediction 
performance for new drug development than for the other two applications, evaluated by the 
difference between ETL and ECV/SCV performance measurements.  
 
Compared among three different prediction models, tDNN performs best in the transfer 
learning task of CTRP ® CCLE, while LightGBM performs best in the other three transfer 
learning tasks. This is different from the cases of drug repurposing and precision oncology, where 
tDNN almost always outperforms LightGBM and sDNN. A possible reason is that the LightGBM 
model has a model complexity lower than those of DNN models, measured by the number of 
trainable parameters. Thus, it is more generalizable for prediction on new drugs, especially when 
the training data include very few drugs. With any of the three prediction models, ETL always 
statistically significantly outperforms SCV and ECV (p-values £ 0.05), except only the comparison 
of ETL (with sDNN) and SCV (with sDNN) for the transfer learning tasks on the GCSI dataset 
when the prediction performance is evaluated by the correlation coefficient. The result shows the 
benefit of using ensemble transfer learning for new drug development.  
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Prediction Performance of Transfer Learning Using Individual Model Without 
Ensemble  
  
Since we have performed ensemble transfer learning (ETL), it is straightforward to 
calculate the prediction performance of transfer learning using an individual model trained on the 
source data without ensemble prediction, which is called standard transfer learning (STL). Detail 
results of STL cannot be presented here due to the large number of models trained in the analysis, 
but we can summarize the major observations on the results. For all three prediction models, STL 
sometimes does not produce a prediction performance better than those of SCV and ECV in the 
drug repurposing and precision oncology applications. But ETL has been shown to dominantly 
outperform SCV and ECV for these two applications, which indicates the importance of using 
transfer learning and ensemble prediction simultaneously for drug response prediction. For the 
more challenging application of new drug development, we find STL almost always outperforms 
SCV and ECV, while ETL further improves the prediction performance. 
 
 
 
Discussion 
 
Compared to existing works, our study is the first research attempt of its kind, which can 
be summarized from three aspects. First, we investigate whether transfer learning improves the 
performance of general response prediction models for multiple cancer types and drugs including 
new drugs not used in model training, whereas existing works focus on building drug-specific 
prediction models through transfer learning. Our prediction task is more challenging. Second, we 
studied the power of transfer learning in three drug response prediction applications including drug 
repurposing, precision oncology, and drug development based on different data partition and 
selection schemes in cross-validation, which to our knowledge has not been investigated before. 
Third, unlike previous transfer learning studies that emphasize building transformations of features 
and drug response values between datasets [Dhruba et al., 2018], we study the power of the classic 
transfer learning scheme that trains a prediction model on the source data and then refines it on the 
target data. We also extend the classic scheme via ensemble and show the benefit of performing 
ensemble transfer learning. Although the distribution of drug response varies between datasets 
(Fig. 1) and the same treatments (pairs of drugs and CCLs) might have quite different response 
values in different datasets [Dhruba et al., 2018], indicating the existence of variation between 
datasets, transfer learning by model refinement on the target dataset seems to overcome this gap 
to certain extent. 
 
We applied transfer learning with three different prediction models, including LightGBM, 
sDNN (single-network DNN), and tDNN (two-subnetwork DNN). In transfer learning with DNN 
models, we also tried freezing the parameters of the bottom 4 hidden layers and adjusting only the 
parameters associated with the top 3 hidden layers and the dropout rate in the model refinement 
stage. The obtained prediction performance was worse than what we got when freezing only the 
bottom 2 hidden layers, indicating the importance of having sufficient layers trainable in model 
refinement for transfer learning.
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Table 3     Comparison on the prediction performance of standard cross-validation (SCV), ensemble cross-validation (ECV), and 
ensemble transfer learning (ETL) for drug repurposing application 
 
Target Source Model RMSE (SCV) RMSE (ECV) RMSE (ETL) 
P-value 
(RMSE, 
SCV vs. 
ETL) 
P-value 
(RMSE, 
ECV vs. 
ETL) 
Cor (SCV) Cor (ECV) Cor (ETL) 
P-value 
(Cor, 
SCV vs. 
ETL) 
P-value 
(Cor, 
ECV vs. 
ETL) 
CCLE  CTRP  
lightGBM 0.0895(0.0007) 0.0872(0.0009) 0.0827(0.0007) 2.30E-11 1.36E-08 0.8313(0.0029) 0.8403(0.0037) 0.8581(0.0023) 4.30E-11 1.82E-08 
sDNN 0.0895(0.0013) 0.0863(0.0010) 0.0812(0.0007) 3.13E-08 4.17E-07 0.8341(0.0050) 0.8466(0.0045) 0.8672(0.0030) 1.97E-08 4.72E-07 
tDNN 0.0918(0.0009) 0.0867(0.0009) 0.0756(0.0005) 4.96E-12 7.66E-11 0.8236(0.0033) 0.8435(0.0030) 0.8841(0.0025) 2.85E-12 3.81E-11 
CCLE  GDSC  
lightGBM 0.0895(0.0007) 0.0872(0.0009) 0.0839(0.0009) 5.06E-09 2.52E-07 0.8313(0.0029) 0.8403(0.0037) 0.8535(0.0035) 8.89E-10 3.13E-08 
sDNN 0.0895(0.0013) 0.0863(0.0010) 0.0838(0.0008) 3.71E-07 2.43E-06 0.8341(0.0050) 0.8466(0.0045) 0.8562(0.0037) 6.10E-07 1.42E-05 
tDNN 0.0918(0.0009) 0.0867(0.0009) 0.0811(0.0007) 2.85E-10 9.30E-08 0.8236(0.0033) 0.8435(0.0030) 0.8654(0.0022) 1.25E-10 1.55E-08 
GCSI  CTRP  
lightGBM 0.1168(0.0005) 0.1142(0.0007) 0.1063(0.0015) 2.08E-09 3.89E-08 0.7889(0.0018) 0.7992(0.0017) 0.8293(0.0048) 2.11E-10 3.85E-09 
sDNN 0.1167(0.0025) 0.1119(0.0017) 0.1051(0.0014) 7.05E-07 1.57E-06 0.7956(0.0111) 0.8118(0.0057) 0.8384(0.0047) 2.13E-06 1.26E-06 
tDNN 0.1177(0.0032) 0.1109(0.0014) 0.0962(0.0018) 7.93E-09 4.92E-09 0.7923(0.0105) 0.8133(0.0050) 0.8633(0.0055) 1.72E-08 4.97E-09 
GCSI  GDSC  
lightGBM 0.1168(0.0005) 0.1142(0.0007) 0.1059(0.0015) 1.99E-09 4.93E-08 0.7889(0.0018) 0.7992(0.0017) 0.8321(0.0056) 7.83E-10 7.97E-09 
sDNN 0.1167(0.0025) 0.1119(0.0017) 0.1047(0.0021) 4.92E-06 1.57E-05 0.7956(0.0111) 0.8118(0.0057) 0.8419(0.0048) 2.43E-06 9.13E-07 
tDNN 0.1177(0.0032) 0.1109(0.0014) 0.0995(0.0017) 1.76E-09 1.12E-09 0.7923(0.0105) 0.8133(0.0050) 0.854(0.0052) 1.54E-09 9.77E-11 
RMSE indicates the square root of mean square error. Cor indicates the Pearson correlation coefficient. In the RMSE and Cor columns, the number before a 
parenthesis is the average prediction performance and the number in a parenthesis is the standard deviation, calculated across 10 cross-validation trials. The p-
values are generated by pairwise t-tests and indicate how significantly the prediction performance of ETL differs from those of SCV and ECV. SCV vs. ETL 
indicates comparison of SCV and ETL. ECV vs. ETL indicates comparison of ECV and ETL. The best average prediction performance for each transfer learning 
task is indicated with bold. 
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Table 4     Comparison on the prediction performance of standard cross-validation (SCV), ensemble cross-validation (ECV), and 
ensemble transfer learning (ETL) for precision oncology application 
 
Target Source Model RMSE (SCV) RMSE (ECV) RMSE (ETL) 
P-value 
(RMSE, 
SCV vs. 
ETL) 
P-value 
(RMSE, 
ECV vs. 
ETL) 
Cor (SCV) Cor (ECV) Cor (ETL) 
P-value 
(Cor, 
SCV vs. 
ETL) 
P-value 
(Cor, 
ECV vs. 
ETL) 
CCLE CTRP 
lightGBM 0.0913(0.0015) 0.0894(0.0015) 0.087(0.0016) 6.43E-06 1.08E-04 0.8245(0.0045) 0.8325(0.0047) 0.8419(0.0056) 3.75E-06 8.75E-05 
sDNN 0.0915(0.0014) 0.0886(0.0009) 0.0858(0.0014) 5.99E-06 5.27E-07 0.8275(0.0052) 0.8385(0.0041) 0.8479(0.0049) 3.67E-06 2.90E-05 
tDNN 0.0909(0.0013) 0.0882(0.0009) 0.0856(0.0014) 2.39E-06 3.89E-05 0.8293(0.0040) 0.8386(0.0038) 0.8476(0.0037) 2.69E-06 1.46E-04 
CCLE GDSC 
lightGBM 0.0913(0.0015) 0.0894(0.0015) 0.0877(0.0014) 5.37E-07 1.58E-04 0.8245(0.0045) 0.8325(0.0047) 0.8389(0.0045) 6.01E-07 1.80E-04 
sDNN 0.0915(0.0014) 0.0886(0.0009) 0.0888(0.0013) 3.27E-04 3.28E-01 0.8275(0.0052) 0.8385(0.0041) 0.8366(0.0038) 1.26E-05 4.86E-03 
tDNN 0.0909(0.0013) 0.0882(0.0009) 0.0869(0.0012) 2.55E-05 3.87E-03 0.8293(0.0040) 0.8386(0.0038) 0.8428(0.0040) 1.22E-04 1.07E-02 
GCSI CTRP 
lightGBM 0.1186(0.0023) 0.116(0.0026) 0.1118(0.0029) 7.89E-05 1.75E-03 0.783(0.0090) 0.7929(0.0094) 0.8087(0.0109) 9.27E-05 1.69E-03 
sDNN 0.123(0.0043) 0.1218(0.0033) 0.1118(0.0016) 1.25E-05 9.55E-06 0.7798(0.0160) 0.7938(0.0082) 0.8119(0.0049) 1.14E-04 5.43E-05 
tDNN 0.1237(0.0043) 0.118(0.0029) 0.1085(0.0012) 3.36E-06 5.19E-06 0.7804(0.0084) 0.7989(0.0083) 0.8228(0.0042) 2.83E-07 2.44E-05 
GCSI GDSC 
lightGBM 0.1186(0.0023) 0.116(0.0026) 0.1099(0.0020) 8.89E-08 6.55E-06 0.783(0.0090) 0.7929(0.0094) 0.8162(0.0072) 1.59E-07 7.10E-06 
sDNN 0.123(0.0043) 0.1218(0.0033) 0.1106(0.0016) 6.42E-06 3.48E-06 0.7798(0.0160) 0.7938(0.0082) 0.8156(0.0063) 3.76E-05 6.37E-07 
tDNN 0.1237(0.0043) 0.118(0.0029) 0.1076(0.0015) 2.34E-06 6.80E-07 0.7804(0.0084) 0.7989(0.0083) 0.8258(0.0046) 4.06E-08 2.86E-07 
RMSE indicates the square root of mean square error. Cor indicates the Pearson correlation coefficient. In the RMSE and Cor columns, the number before a 
parenthesis is the average prediction performance and the number in a parenthesis is the standard deviation, calculated across 10 cross-validation trials. The p-
values are generated by pairwise t-tests and indicate how significantly the prediction performance of ETL differs from those of SCV and ECV. SCV vs. ETL 
indicates comparison of SCV and ETL. ECV vs. ETL indicates comparison of ECV and ETL. The best average prediction performance for each transfer learning 
task is indicated with bold. 
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Table 5     Comparison on the prediction performance of standard cross-validation (SCV), ensemble cross-validation (ECV), and 
ensemble transfer learning (ETL) for the application of new drug development. 
 
Target Source Model RMSE (SCV) RMSE (ECV) RMSE (ETL) 
P-value 
(RMSE, 
SCV vs. 
ETL) 
P-value 
(RMSE, 
ECV vs. 
ETL) 
Cor (SCV) Cor (ECV) Cor (ETL) 
P-value 
(Cor, 
SCV vs. 
ETL) 
P-value 
(Cor, 
ECV vs. 
ETL) 
CCLE CTRP 
lightGBM 0.1828(0.0249) 0.1826(0.0249) 0.1589(0.0125) 2.32E-02 2.42E-02 0.0739(0.0781) 0.0778(0.0815) 0.3742(0.1490) 1.52E-04 1.45E-04 
sDNN 0.2132(0.0608) 0.1964(0.0460) 0.158(0.0152) 3.20E-02 4.52E-02 0.0762(0.0803) 0.0685(0.1638) 0.4455(0.0965) 3.77E-05 8.99E-04 
tDNN 0.206(0.0637) 0.205(0.0602) 0.1553(0.0176) 4.98E-02 4.46E-02 0.0917(0.1589) 0.0937(0.1446) 0.4667(0.1172) 1.20E-04 6.99E-05 
CCLE GDSC 
lightGBM 0.1828(0.0249) 0.1826(0.0249) 0.1283(0.0053) 9.11E-05 9.57E-05 0.0739(0.0781) 0.0778(0.0815) 0.6301(0.0525) 2.52E-09 2.80E-09 
sDNN 0.2132(0.0608) 0.1964(0.0460) 0.146(0.0201) 1.04E-02 8.23E-03 0.0762(0.0803) 0.0685(0.1638) 0.5717(0.0539) 5.76E-08 8.65E-06 
tDNN 0.206(0.0637) 0.205(0.0602) 0.1412(0.0214) 2.28E-02 1.92E-02 0.0917(0.1589) 0.0937(0.1446) 0.6124(0.0638) 1.09E-05 6.65E-06 
GCSI CTRP 
lightGBM 0.2491(0.0402) 0.249(0.0401) 0.1975(0.0197) 3.03E-03 3.02E-03 0.163(0.0643) 0.1707(0.0599) 0.396(0.0366) 1.41E-05 1.54E-05 
sDNN 0.2804(0.0584) 0.3042(0.0693) 0.2243(0.0346) 1.54E-02 1.57E-02 0.0172(0.2006) -0.2031(0.1689) 0.2231(0.1606) 8.78E-02 1.27E-03 
tDNN 0.3043(0.0931) 0.2988(0.0670) 0.215(0.0348) 1.97E-02 6.88E-03 -0.1835(0.1726) -0.1463(0.2150) 0.3707(0.0751) 8.90E-06 1.17E-04 
GCSI GDSC 
lightGBM 0.2491(0.0402) 0.249(0.0401) 0.2075(0.0268) 8.21E-03 8.23E-03 0.163(0.0643) 0.1707(0.0599) 0.3878(0.0513) 3.11E-05 3.63E-05 
sDNN 0.2804(0.0584) 0.3042(0.0693) 0.2255(0.0239) 2.42E-02 8.93E-03 0.0172(0.2006) -0.2031(0.1689) 0.1092(0.2477) 4.89E-01 2.36E-03 
tDNN 0.3043(0.0931) 0.2988(0.0670) 0.2148(0.0295) 2.13E-02 7.11E-03 -0.1835(0.1726) -0.1463(0.2150) 0.3147(0.0983) 5.37E-06 2.87E-04 
RMSE indicates the square root of mean square error. Cor indicates the Pearson correlation coefficient. In the RMSE and Cor columns, the number before a 
parenthesis is the average prediction performance and the number in a parenthesis is the standard deviation, calculated across 10 cross-validation trials. The p-
values are generated by pairwise t-tests and indicate how significantly the prediction performance of ETL differs from those of SCV and ECV. SCV vs. ETL 
indicates comparison of SCV and ETL. ECV vs. ETL indicates comparison of ECV and ETL. The best average prediction performance for each transfer learning 
task is indicated with bold. 
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Prediction of anti-cancer drug response is a challenging task due to multiple reasons. First, 
the size of the currently available drug screening data is small compared to the huge dimensionality 
of cancer molecular/genomic system and the huge space of drug chemical structure, which forms 
a small-sample-size problem with insufficient data. Second, the drug mechanism of action (MoA) 
usually involves a complex chain of biochemical reactions and genomic regulations that might not 
be fully measured by existing experimental techniques. Thus, current data, such as gene expression 
and drug descriptors, might not be sufficient for modeling the drug action on tumors. Third, there 
is a gap between the current biological models used for drug screening and the therapeutic targets, 
patient tumors. The ultimate goal of predicting drug response is to either recommend an existing 
drug or design a new drug for treating a particular patient. Biological models currently used for 
drug screening mainly include CLLs and patient derived models, such as xenografts (PDXs) [Gao 
et al., 2015] and organoids (PDOrgs) [Aboulkheyr et al., 2018]. These biological models are 
different from each other and also different from the real patient tumors, leading to the variations 
of their drug responses. CLL drug screening data are relatively more abundant than both 
PDX/PDOrg drug screening data and patient treatment response data. Our work is a pilot study 
that builds general drug response prediction models through transfer learning, which can be helpful 
for future studies on transfer learning between different biological models and patients. 
 
In future research, there are ways to potentially improve the drug response prediction 
accuracy. To better characterize the complex interaction between drug and tumor molecular system, 
existing knowledge of drug MoA and tumor genomic regulation mechanism can be integrated into 
the prediction model. Examples of drug MoA information are drug target genes and drug MoA 
categories. Examples of information about genomic regulation mechanism can be genetic 
pathways and protein-protein interactions affected by the drug MoA. Measurements or predictions 
on the binding affinities between drugs and target proteins may contribute to the prediction of drug 
response. Suitable feature selection and data representation may also be helpful. Gene selection 
methods such as co-expression extrapolation (COXEN) [Lee et al., 2007] can be used to identify 
genes that are both predictive for drug response and generalizable between different biological 
models and patient tumors. Chemical structures of drugs can be represented by not only numeric 
descriptors or fingerprints, but also by 2D/3D graphs/images that can be learned by deep neural 
networks.  
 
 
Conclusion 
 
 We developed the first ensemble transfer learning framework that builds general prediction 
models for predicting anti-cancer drug response. The transfer learning pipeline was implemented 
with three different prediction models including LightGBM, sDNN (single-network DNN), and 
tDNN (two-subnetwork DNN). Uniquely, we investigated the performance of the transfer learning 
pipeline for three drug response prediction applications including drug repurposing, precision 
oncology, and new drug development, based on in vitro drug screening data. Our results 
demonstrate the benefit of applying ensemble transfer learning in all of the three applications. For 
the comparison between three different prediction models, tDNN performs best in the drug 
repurposing and precision oncology applications, while LightGBM outperforms tDNN in 3 out of 
the 4 transfer learning tasks for the more challenging application of new drug development. Our 
work is a pilot study of transfer learning for building general drug response prediction models that 
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are not specific to a particular drug, which may provide guidance for future research on transfer 
learning of drug response prediction between different biological models and patients. 
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